Tamsulosin Hydrochloride
Product Images NDC 42254-012

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 42254-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (1ceb560b 1a62 408d 8e30 23113e8c9dd3 01)

Chemical structure of Tamsulosin Hydrochloride showing its molecular formula with annotated functional groups and hydrochloride salt.*

FDA Label Image

Figure1 (1ceb560b 1a62 408d 8e30 23113e8c9dd3 02)

A pharmacokinetic plasma concentration versus time graph for Tamsulosin Hydrochloride showing comparison between fasted and fed states. The y-axis represents plasma concentration in ng/mL, and the x-axis shows time in hours up to 36 hours. The graph displays two curves: a dashed line indicating the fasted state and a solid line indicating the fed state.*

FDA Label Image

Figure 2a (1ceb560b 1a62 408d 8e30 23113e8c9dd3 03)

A line graph showing the mean change over weeks of treatment for TAMSULOSIN HYDROCHLORIDE at doses of 0.8 mg and 0.4 mg compared to placebo. The x-axis represents duration of treatment in weeks (from baseline to 13 weeks), and the y-axis shows mean change values, illustrating greater improvement with higher dose over time.*

FDA Label Image

Figure 2b (1ceb560b 1a62 408d 8e30 23113e8c9dd3 04)

A line graph depicting mean change on the y-axis against duration of treatment in weeks on the x-axis. Three treatment groups are compared: 0.3 mg, 0.4 mg, and placebo, with sample sizes noted below each time point. The graph shows trends over 13 weeks and includes an LOCF (last observation carried forward) measurement. The 0.3 mg and 0.4 mg treatments demonstrate greater mean change than placebo over time.*

FDA Label Image

Figure3a (1ceb560b 1a62 408d 8e30 23113e8c9dd3 05)

A line graph depicting mean change in mL/sec over weeks of treatment duration for TAMSULOSIN HYDROCHLORIDE at 0.4 mg and 0.8 mg doses compared to placebo. The x-axis represents treatment duration in weeks, and the y-axis shows mean change. Data points indicate sample sizes at each interval, with treatment groups showing greater mean change compared to placebo over time.*

FDA Label Image

Figure3b (1ceb560b 1a62 408d 8e30 23113e8c9dd3 06)

Line graph showing mean change in mL/sec over duration of treatment in weeks, comparing three groups: 0.8 mg, 0.4 mg, and placebo. The y-axis represents mean change, ranging from 0 to 3.0 mL/sec, and the x-axis shows treatment duration up to 13 weeks. The graph includes sample sizes at various time points.*

FDA Label Image

Tamsulosin HCl 0.4mg (1ceb560b 1a62 408d 8e30 23113e8c9dd3 07)

Tamsulosin HCl 0.4mg capsule label displaying the product name, strength, and dosage form. The label indicates a 30-capsule package and specifies that each capsule contains 0.4mg of Tamsulosin HCl. It includes the NDC 42254-012-30, with manufacturer details pointing to Wockhardt Limited, Mumbai, India. The packaging is supplied by Physician Partner, Thousand Oaks, CA, with storage instructions noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.